P1116: SAFETY, PHARMACOKINETIC (PK), PHARMACODYNAMIC (PD) AND ACTIVITY OF THE HIGHLY SELECTIVE PHOSPHOINOSITIDE 3-KINASE INHIBITOR DELTA (PI3KΔ) INHIBITOR IOA-244 IN PATIENTS WITH... by C. Carlostella, M. Lahn, T. Hammett, L. van der Veen, Z. Johnson, C. Pickering, A. Santoro

Get full text

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA by Allicia C Girvan, Gebra C Carter, Li Li, Anna Kaltenboeck, Jasmina Ivanova, Maria Koh, Jessi Stevens, Eleanor Hayes-Larson, Michael M Lahn

Get full text

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer by Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane, Irene Braña, Elisabet Sicart, Colin Miles, Michael M Lahn, Malcolm I Mitchell, Jordi Rodon

Get full text

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. by Gianluigi Giannelli, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Ann Cleverly, Claire Smith, Shawn T Estrem, Michael Man, Shuaicheng Wang, Michael M Lahn, Eric Raymond, Karim A Benhadji, Sandrine Faivre

Get full text

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. by Gianluigi Giannelli, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Ann Cleverly, Claire Smith, Shawn T Estrem, Michael Man, Shuaicheng Wang, Michael M Lahn, Eric Raymond, Karim A Benhadji, Sandrine Faivre

Get full text

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors by M.A. Deken, K. Niewola-Staszkowska, O. Peyruchaud, N. Mikulčić, M. Antolić, P. Shah, A. Cheasty, A. Tagliavini, A. Nizzardo, M. Pergher, L. Ziviani, S. Milleri, C. Pickering, M. Lahn, L. van der Veen, G. Di Conza, Z. Johnson

Get full text